Activity Overview
This online, on-demand virtual symposium brings together renowned experts in the management of endocrine-sensitive HR+/HER2− metastatic breast cancer (mBC) with a focus on treatment options following first-line endocrine therapy plus a CDK4/6 inhibitor. In this educational program, these experts discuss the role of mutational testing to guide therapy selection and the efficacy and safety of next-generation targeted therapies, including oral SERDs and PI3K, AKT, and mTOR inhibitors. The program also addresses best practices for managing adverse effects and uses a case-based format to provide practical insights to improve patient care.
This educational activity is an archive of the live presentation held on May 7, 2026.
Target Audience
This educational program is primarily directed toward community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other health care providers involved in the treatment of metastatic breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply guideline-concordant approaches for molecular testing in patients with HR+/HER2− mBC across the disease continuum
- Evaluate recent real-world evidence providing practical insights into the use of targeted treatment strategies for HR+/HER2− mBC
- Integrate clinical trial and real-world data alongside patient- and disease-specific characteristics into personalized treatment decisions for patients with HR+/HER2− mBC
- Develop evidence-based strategies for monitoring and mitigating adverse effects associated with targeted therapies for HR+/HER2− mBC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here